Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.
Historique des changements
First seen 28 Sept 2026, last checked 22 Nov 2026. 20 recorded versions.
- 22 Oct 2026 · 3be0dbd0b3b8
- 22 Oct 2026 · 796737bf1518
- 21 Oct 2026 · 7af4a767ac5d
- 20 Oct 2026 · fe638a78cba3
- 19 Oct 2026 · bf6b04eebf9d
- 17 Oct 2026 · 5dc7e7767432
- 16 Oct 2026 · b4d598d2ed0c
- 15 Oct 2026 · 1630cd7f149c
- 14 Oct 2026 · 5d946efd91c3
- 13 Oct 2026 · 6bfd906dcce6
- 12 Oct 2026 · c87b8b1c1102
- 11 Oct 2026 · a8352d83cce6
- 10 Oct 2026 · 1630cd7f149c
- 09 Oct 2026 · c18337de14dc
- 08 Oct 2026 · 5dc7e7767432
- 07 Oct 2026 · b4d598d2ed0c
- 06 Oct 2026 · 2125c1fbe178
- 05 Oct 2026 · f6646dae264f
- 04 Oct 2026 · 441eddd5d3bc
- 03 Oct 2026 · 1f13e933759b